| Cite this article: |
| ZHANG Li,WANG Yanqing,WANG Yan,LIU Jianrong,ZHANG Xiaomin.Mechanism study of Tirzepatide inhibiting proliferation and inflammatory response in psoriatic HaCaT cells via the FOXO1/CCND1 signaling pathway[J].Journal Of Pharmaceutical Research,2026,45(9):983-989,1012[Click to copy] |
|
| 摘要: |
| 目的 替尔泊肽作为新型胰高血糖素样肽-1(GLP-1)/抑胃肽(GIP)双受体激动剂,其治疗潜力尚未在银屑病中得到阐明。本研究旨在探讨替尔泊肽对银屑病样角质形成细胞模型的影响及其作用机制。方法 首先,通过生物信息学分析筛选替尔泊肽的潜在作用靶点及通路。进而,采用M5细胞因子混合物刺激HaCaT细胞建立模型,设立对照组、模型组、替尔泊肽干预组及替尔泊肽联合FOXO1抑制剂组。通过CCK-8法评估细胞增殖活力,蛋白质印迹法检测FOXO1磷酸化水平与细胞周期蛋白D1(CCND1)表达,并对炎症反应相关指标进行检测。结果 生物信息学分析提示CCND1是关键靶点,并富集于FOXO信号通路。体外实验表明,替尔泊肽能有效抑制M5诱导的HaCaT细胞过度增殖,并减轻炎症反应。在机制上,替尔泊肽处理降低了p-FOXO1/FOXO1比值,同时下调了其下游靶点CCND1的蛋白表达。而FOXO1抑制剂则逆转了替尔泊肽的上述效应。结论 本研究提示,替尔泊肽可能通过FOXO1/CCND1信号通路,抑制角质形成细胞的异常增殖与炎症反应,从而为银屑病治疗提供了新的潜在策略与实验依据。 |
| 关键词: 替尔泊肽 FOXO1 细胞周期蛋白D1 银屑病 HaCaT细胞 炎症 网络药理学 |
| DOI:10.13506/j.cnki.jpr.2026.09.004 |
| 基金项目:山西省高等学校科技创新项目(No.2022L156) |
|
Received Date:March 02, 2026
Revision Date:May 14, 2026
Publication Date:September 30, 2026
|
|
| Mechanism study of Tirzepatide inhibiting proliferation and inflammatory response in psoriatic HaCaT cells via the FOXO1/CCND1 signaling pathway |
| ZHANG Li1,WANG Yanqing1,WANG Yan1,LIU Jianrong1,ZHANG Xiaomin2 |
| (1.Department of Dermatology, Second Hospital of Shanxi Medical University,Taiyuan 030001,China;2.Department of Neurology, Second Hospital of Shanxi Medical University, Taiyuan 030001,China) |
| Abstract: |
| Objective The therapeutic potential of tirzepatide, a novel GLP-1/GIP dual receptor agonist, has not been elucidated in psoriasis. This study aimed to investigate the effects of tirzepatide on a psoriasis-like keratinocyte model and its underlying mechanisms.Methods First, bioinformatics analysis was used to screen potential targets and pathways for tirzepatide. Subsequently, HaCaT cells were stimulated with an M5 cytokine mixture to establish a psoriasis-like keratinocyte model. Groups included a control group, a model group, a tirzepatide intervention group, and a tirzepatide combined with FOXO1 inhibitor group. Cell proliferation was assessed using the CCK-8 assay, FOXO1 phosphorylation levels and CCND1 protein expression were detected by Western blotting, and inflammatory markers were evaluated.Results Bioinformatics analysis indicated CCND1 as a key target enriched in the FOXO signaling pathway. In vitro experiments demonstrated that tirzepatide effectively suppressed M5-induced excessive proliferation in HaCaT cells and alleviated inflammatory responses. Mechanistically, tirzepatide treatment reduced the p-FOXO1/FOXO1 ratio while downregulating the protein expression of its downstream target CCND1. FOXO1 inhibitors reversed the aforementioned effects of tirzepatide.Conclusion This study suggests that tirzepatide may suppress abnormal proliferation and inflammatory responses in keratinocytes via the FOXO1/CCND1 signaling pathway, thereby providing a novel potential therapeutic strategy and experimental basis for psoriasis treatment. |
| Key words: Tirzepatide FOXO1 CCND1 Psoriasis HaCaT Inflammation Network pharmacology |